Budesonide for COVID-19: real-time analysis of all 4 studies

Home

Database of all budesonide COVID-19 studies. Submit updates/corrections.


Jul 20	In Vitro	Heinen et al., Viruses, doi:10.3390/v13071411 (Peer Reviewed) (In Vitro)	in vitro	Antiviral Effect of Budesonide against SARS-CoV-2
	Details In Vitro study showing dose-dependent inhibition of SARS-CoV-2 with budesonide.
Jul 20	Details Source PDF In Vitro In Vitro
	Heinen et al., Viruses, doi:10.3390/v13071411 (Peer Reviewed) (In Vitro)
	Antiviral Effect of Budesonide against SARS-CoV-2
	In Vitro study showing dose-dependent inhibition of SARS-CoV-2 with budesonide. Heinen et al., 7/20/2021, peer-reviewed, 6 authors.
	Share Tweet Submit Corrections or Comments
May 5	In Vitro	Konduri et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro)	in vitro	ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
	Details In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide..
May 5	Details Source PDF In Vitro In Vitro
	Konduri et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro)
	ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
	In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide is a formulation for sustained administration of a low dose of budesonide using a vehicle similar to lung surfactant. Konduri et al., 5/5/2021, preprint, 10 authors.
	Share Tweet Submit Corrections or Comments
Apr 12	Late	Yu et al., The Lancet, doi:10.1016/S0140-6736(21)01744-X (preprint 4/12/21) (Peer Reviewed)	death, ↓39.1%, p=0.45	Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
	Details Interim results from the PRINCIPLE trial, 1,073 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment. ISRCTN86534580.
Apr 12	Details Source PDF Late treatment study Late treatment study
	Yu et al., The Lancet, doi:10.1016/S0140-6736(21)01744-X (preprint 4/12/21) (Peer Reviewed)
	Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
	Interim results from the PRINCIPLE trial, 1,073 treated with budesonide starting a median of 6 days after symptom onset, showing lower hospitalization/death, and faster recovery with treatment. ISRCTN86534580. risk of death, 39.1% lower, RR 0.61, p = 0.45, treatment 6 of 787 (0.8%), control 10 of 799 (1.3%). risk of mechanical ventilation, 6.0% lower, RR 0.94, p = 1.00, treatment 13 of 776 (1.7%), control 14 of 784 (1.8%). risk of ICU admission, 52.0% lower, RR 0.48, p = 0.07, treatment 10 of 771 (1.3%), control 21 of 779 (2.7%). risk of combined hospitalization/death, 25.0% lower, RR 0.75, p = 0.96, treatment 72 of 787 (9.1%), control 116 of 1069 (10.9%), adjusted, day 28. recovery time, 17.4% lower, relative time 0.83, p = 0.001, treatment 787, control 1069, adjusted. Yu et al., 4/12/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 24 authors.
	Share Tweet Submit Corrections or Comments
Feb 8	Early	Ramakrishnan et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed)	hosp./ER, ↓81.8%, p=0.02	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
	Details RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14.
Feb 8	Details Source PDF Early treatment study Early treatment study
	Ramakrishnan et al., Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00160-0 (preprint 2/8) (Peer Reviewed)
	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
	RCT with 73 budesonide patients and 73 control patients, showing significantly lower combined risk of an ER visit or hospitalization, and lower risk of no recovery at day 14. risk of hospitalization/ER, 81.8% lower, RR 0.18, p = 0.02, treatment 2 of 73 (2.7%), control 11 of 73 (15.1%), ITT. risk of hospitalization/ER, 90.1% lower, RR 0.10, p = 0.004, treatment 1 of 70 (1.4%), control 10 of 69 (14.5%), PP. risk of no recovery, 67.1% lower, RR 0.33, p = 0.003, treatment 7 of 70 (10.0%), control 21 of 69 (30.4%), PP, day 14. recovery time, 12.5% lower, relative time 0.88, treatment 70, control 69, PP. Ramakrishnan et al., 2/8/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 24 authors.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit